Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03806296 · ClinicalTrials.gov registry record · NA
Delayed Sleep Timing in Teens Study
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 142
- Enrollment target
NCT03806296: Completed NA study, sponsored by University of Pittsburgh.
NCT03806296 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 142 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03806296, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 142 participants
- Enrollment target
Study Summary
This study will (1) comprehensively characterize the substance use disorder (SUD) risk profile associated with adolescent Delayed Sleep Phase (DSP), and (2) probe whether SUD risk is diminished by altering sleep/circadian timing.
Primary Outcome
Total Sleep Time as determined by wrist actigraphy data (averaged across weekdays during 1 week of T1 and during 2 weeks of T2)
Interventions
- OTHER Increase morning bright light
- OTHER Decrease evening blue light
- BEHAVIORAL Monitor sleep, mood, and substance use
- BEHAVIORAL Sleep scheduling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2024-11-30 |
| Phase | NA |
What the finished NCT03806296 record still lists
NCT03806296 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 4 interventions - of which Increase morning bright light is the first listed.
NCT03806296 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03806296 about?
NCT03806296 is a clinical study titled "Delayed Sleep Timing in Teens Study". This study will (1) comprehensively characterize the substance use disorder (SUD) risk profile associated with adolescent Delayed Sleep Phase (DSP), and (2) probe whether SUD risk is diminished by altering sleep/circadian timing.
What is the current status of trial NCT03806296?
This trial is currently completed. It is a NA study. The enrollment target is 142 participants. The study started on 2018-12-03. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT03806296?
The interventions under investigation include: Increase morning bright light (OTHER), Decrease evening blue light (OTHER), Monitor sleep, mood, and substance use (BEHAVIORAL), Sleep scheduling (BEHAVIORAL).
Who is sponsoring clinical trial NCT03806296?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03806296's enrollment target sits among peer trials
142 711th of 2000 higher than 1,289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI